Comunicato stampa EMA su Multaq (dronedarone)
Disponibili on line importanti informazioni di sicurezza da parte dell'Agenzia Europea dei Medicinali (EMA) sul medicinale Multaq (dronedarone),
Undefined
Disponibili on line importanti informazioni di sicurezza da parte dell'Agenzia Europea dei Medicinali (EMA) sul medicinale Multaq (dronedarone),
Patients may potentially receive either concentration (6 mg/mL or 12 mg/mL) from their pharmacy during the next influenza season (2011-2012).
Products marketed as dietary supplements contain sibutramine, which may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias or stroke.
Product marketed as a dietary supplement contains sibutramine, which may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias or stroke.
Increased Risk of Post-transplant Lymphoproliferative Disorder (PTLD) and Progressive Multifocal Leukoencephalopathy (PML).
Benefits and risks of valproate sodium and related products should be carefully weighed when prescribing these drugs to women of childbearing age.
One lot recalled due to the presence of trace amounts of a 2,4,6-tribromoanisole (TBA), which has been associated with temporary and non-serious gastrointestinal symptoms.
Active ingredient calcium oxide can cause severe burns, particularly to areas of thin or sensitive skin such as the face, around the eyes, and genitalia.
Risk of increase of acetaminophen dose, which may result in liver toxicity, especially in patients on other acetaminophen containing medications.
Recalled bottles may contain incorrect tablets, patients may unintentionally take butalbital and caffeine instead of hydrocodone.
80.211.154.110